The biotechnology company Novavax announced on Monday that it has completed enrollment of its PREVENT-19 trial, a Phase 3 study of its Covid-19 vaccine in the United States and Mexico.
The trial has enrolled 30,000 volunteers across 118 locations, according to the announcement.
In January, Novavax announced that early results from a Phase 3 trial in the UK show its coronavirus vaccine has an efficacy of 89.3%.
"The full enrollment of PREVENT-19 is another important step in building a body of evidence to demonstrate that NVX-CoV2373 will be safe and effective across diverse, representative populations," Gregory M. Glenn, president of research and development for Novavax, said in the company's announcement.
The company's announcement also included the diversity breakdown of its trial participants, with 20% identifying as LatinX, 13% as Black, 6% as Native American, and 5% as Asian American.
The announcement noted that 13% of volunteers are 65 and older.